GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » PS Ratio

Verve Therapeutics (Verve Therapeutics) PS Ratio : 38.40 (As of May. 03, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Verve Therapeutics's share price is $6.49. Verve Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.17. Hence, Verve Therapeutics's PS Ratio for today is 38.40.

Good Sign:

Verve Therapeutics Inc stock PS Ratio (=33.55) is close to 2-year low of 33.55

The historical rank and industry rank for Verve Therapeutics's PS Ratio or its related term are showing as below:

VERV' s PS Ratio Range Over the Past 10 Years
Min: 36.33   Med: 218.26   Max: 2543.75
Current: 36.23

During the past 5 years, Verve Therapeutics's highest PS Ratio was 2543.75. The lowest was 36.33. And the median was 218.26.

VERV's PS Ratio is ranked worse than
74.9% of 996 companies
in the Biotechnology industry
Industry Median: 9.035 vs VERV: 36.23

Verve Therapeutics's Revenue per Sharefor the three months ended in Dec. 2023 was $0.06. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.17.

During the past 12 months, the average Revenue per Share Growth Rate of Verve Therapeutics was 408.30% per year.

Back to Basics: PS Ratio


Verve Therapeutics PS Ratio Historical Data

The historical data trend for Verve Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verve Therapeutics PS Ratio Chart

Verve Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 537.50 76.17

Verve Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 537.50 262.18 210.67 108.69 76.17

Competitive Comparison of Verve Therapeutics's PS Ratio

For the Biotechnology subindustry, Verve Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verve Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verve Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Verve Therapeutics's PS Ratio falls into.



Verve Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Verve Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=6.49/0.169
=38.40

Verve Therapeutics's Share Price of today is $6.49.
Verve Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Verve Therapeutics  (NAS:VERV) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Verve Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verve Therapeutics (Verve Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Executives
Krishna Yeshwant director, 10 percent owner C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Allison Dorval officer: Chief Financial Officer C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Fred T. Fiedorek officer: Chief Medical Officer 55 BALDWIN LANE, PRINCETON NJ 08540
Joan Nickerson officer: Chief Administrative Officer C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Andrew Bellinger officer: Chief Scientific Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. other: Member of 10% Group 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan director, 10 percent owner, officer: Chief Executive Officer 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman director, 10 percent owner DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Andrew D. Ashe officer: See Remarks C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Logos Global Management Lp 10 percent owner 1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116

Verve Therapeutics (Verve Therapeutics) Headlines